February 18, 2005 In a day that saw mixed results for market indexes, the Centient Biotech 200 gained 5 points to 3327.40, a .16% move. That result put the CBT 200 between the NYSE Composite, which was higher by .21%, and the Nasdaq, which slipped .13%. But the big news was the FDA Advisory Panel, which was looking into the COX-2 drugs, including Celebrex, Bextra and Vioxx. In the opinion of the panel, all three have cardiovascular risks, but all should remain on the market. We discuss the likely ramifications of the decisions, and we also look at test results from an anti-wrinkle drug developed by Isolagen and a trial of Embrel from Wyeth and Amgen against psoriasis...
